Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Webb

Showing results (11-20 of 323) with videos related to

Pageof 33
Sort By:
Hypertension (Dallas, Tex. : 1979)|November 30, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialNeeraj Dhaun, David J Webb
Lancet (London, England)|May 1, 2007
Value-based pricing of drugs in the UKDavid J Webb, Andrew Walker
British Journal of Clinical Pharmacology|October 1, 2013
Novel therapeutic approaches to chronic kidney diseaseNeeraj Dhaun, David J Webb
Kidney International|October 2, 2013
The road from AKI to CKD: the role of endothelinNeeraj Dhaun, David J Webb
Hypertension (Dallas, Tex. : 1979)|August 25, 2010
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?Neeraj Dhaun, David J Webb
Clinical Journal of the American Society of Nephrology : CJASN|November 14, 2015
Targeting Blood Vessel Stiffness to Protect Kidney FunctionNeeraj Dhaun, David J Webb
Current Hypertension Reports|April 14, 2016
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant HypertensionHafid Narayan, David J Webb
Lancet (London, England)|June 24, 2008
Endothelin-receptor antagonism: the future is brightNeeraj Dhaun, David J Webb
Hypertension (Dallas, Tex. : 1979)|September 7, 2002
Endothelin antagonists and hypertension: a question of dose?Jane Goddard, David J Webb
Heart (British Cardiac Society)|May 19, 2010
Translational research: a priority for health and wealthDavid E Newby, David J Webb
Pageof 33

Showing results (11-20 of 323) with videos related to

Sort By:
Pageof 33
Hypertension (Dallas, Tex. : 1979)|November 30, 2011
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialNeeraj Dhaun, David J Webb
Lancet (London, England)|May 1, 2007
Value-based pricing of drugs in the UKDavid J Webb, Andrew Walker
British Journal of Clinical Pharmacology|October 1, 2013
Novel therapeutic approaches to chronic kidney diseaseNeeraj Dhaun, David J Webb
Kidney International|October 2, 2013
The road from AKI to CKD: the role of endothelinNeeraj Dhaun, David J Webb
Hypertension (Dallas, Tex. : 1979)|August 25, 2010
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?Neeraj Dhaun, David J Webb
Clinical Journal of the American Society of Nephrology : CJASN|November 14, 2015
Targeting Blood Vessel Stiffness to Protect Kidney FunctionNeeraj Dhaun, David J Webb
Current Hypertension Reports|April 14, 2016
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant HypertensionHafid Narayan, David J Webb
Lancet (London, England)|June 24, 2008
Endothelin-receptor antagonism: the future is brightNeeraj Dhaun, David J Webb
Hypertension (Dallas, Tex. : 1979)|September 7, 2002
Endothelin antagonists and hypertension: a question of dose?Jane Goddard, David J Webb
Heart (British Cardiac Society)|May 19, 2010
Translational research: a priority for health and wealthDavid E Newby, David J Webb
Pageof 33